PTO/SB/08A (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

JAN 16 2004 PTO/SB/08A

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Attorney D cket Number	4239-64790
Application Number	10/677,943
Filing Date	October 1, 2003
First Named Inventor	Nelson
Art Unit	1632
Examiner Name	_____

U.S. PATENT DOCUMENTS

Examiner's Initials*	Cite No. (optional)	Number	Date	Name
MS	A1	5,637,300	June 10, 1997	Dunbar *et al.*
MS	A2	6,027,727	Feb. 22, 2000	Harris *et al.*

Examiner's Initials*	Cite No. (optional)	OTHER DOCUMENTS
MS	C1	Bouniol *et al.*, "Endogenous transcription occurs at the 1-cell stage in the mouse embryo," *Experimental Cell Research* 218:57-62, 1995.
	C2	Chattopadhyay *et al.*, "Antiovarian antibody in premature ovarian failure," *Indian J. Med. Sci.* 53(6):254-258, June 1999 (*Abstract only*)
	C3	Damewood *et al.*, "Circulating antiovarian antibodies in premature ovarian failure," *Obstet. Gynecol.* 68(6):850-854, December 1986 (*Abstract only*)
	C4	Damjanovic, "Experimental autoimmune oophoritis. II. Both lymphoid cells and antibodies are successful in adoptive transfer," *Autoimmunity* 9(3):217-223, 1991 (*Abstract only*)
	C5	De Angelo and Michael, "Cellular events associated with autoimmune oophoritis and ovarian tumorigenesis in neonatally thymectomized mice," *J. Reprod. Immunol.* 12(1):63-78, September 1987 (*Abstract only*)
	C6	De Angelo and Michael, "The effect of antisera to thymosin alpha 1 on the course of autoimmune ovarian dysgenesis in neonatally thymectomized mice," *J. Reprod. Immunol.* 11(1):41-53, May 1987 (*Abstract only*)
	C7	Garza *et al.*, "Mechanism of ovarian autoimmunity: induction of T cell and antibody responses by T cell epitope mimicry and epitope spreading," 37(2):87-101, February 1998 (*Abstract only*)
	C8	Govind *et al.*, "Delineation of a conserved B cell epitope on bonnet monkey (Macaca radiate) and human zona pellucida glycoprotein-B by monoclonal antibodies demonstrating inhibition of sperm-egg binding," *Biol. Reprod.* 62(1):67-75, January 2000 (*Abstract only*)
MS	C9	Hoek *et al.*, "Premature ovarian failure and ovarian autoimmunity," *Endocr. Rev.* 18(1):107-134, February 1997 (*Abstract only*)

EXAMINER SIGNATURE:	DATE CONSIDERED: 12/30/05

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.

JAN 16 2004

Attorney Docket Number	4239-64790
Application Number	10/677,943
Filing Date	October 1, 2003
First Named Inventor	Nelson
Art Unit	1632
Examiner Name	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

	C10	Kalantaridou and Nelson, "Autoimmune Premature Ovarian Failure: Of Mice and Women," *JAMWA* 53(1):18-20, 1998
	C11	Kalantaridou and Nelson, "Premature ovarian failure is not premature menopause," *Ann. NY Acad. Sci.*900:393-402, 2000 (*Abstract only*)
	C12	Kobe and Deisenhofer, "Proteins with leucine-rich repeats," *Curr. Opin. Struct. Biol.* 5:409-416, 1995
	C13	Kosiewicz and Michael, "Neonatal thymectomy affects follicle populations before the onset of autoimmune oophoritis in B6A mice," *J. Reprod. Fertil.* 88(2):427-440, March 1990 (*Abstract only*)
	C14	Lou *et al.*, "Rapid Induction of Autoantibodies by Endogenous Ovarian Antigens and Activated T Cells," *J. Immun.*, 156:3535-3540, May 1, 1996 (*Abstract only*)
	C15	Luborsky *et al.*, "Ovarian antibodies, FSH and inhibin B: independent markers associated with unexplained infertility," *Human Reprod.* 15(5):1046-1051, 2000
	C16	Melner and Feltus, "Editorial: AutoImmune Premature Ovarian Failure – Endocrine Aspects of a T Cell Disease," *Endocrin.* 140(8):3401-3403, 1999
	C17	Murray *et al.*, "Reproductive and menstrual history of females with fragile X expansions," *Eur. J. Hum. Genet.* 8(4):247-252, April 2000 (*Abstract only*)
	C18	Rabinowe *et al.*, "Lymphocyte dysfunction in autoimmune oophoritis. Resumption of menses with corticosteroids," *Am. J. Med.* 81(2):347-350, August 1986 (*Abstract only*)
	C19	Sakaguchi *et al.*, "Study on cellular events in postthymectomy autoimmune oophoritis in mice. I. Requirement of Lyt-1 effector cells for oocytes damage after adoptive transfer," *J. Exp. Med.* 156(6):1565-1576, December 1, 1982 (*Abstract only*)
	C20	Sakaguchi *et al.*, "Study on cellular events in postthymectomy autoimmune oophoritis in mice. II. Requirement of Lyt-1 cells in normal femalemice for the prevention of oophoritis," *J. Exp. Med.* 156(6):1577-1586, December 1, 1982 (*Abstract only*)
	C21	Smith *et al.*, "Effector and regulatory cells in autoimmune oophoritis elicited by neonatal thymectomy," *J. Immunol.*147(9):2928-2933, November 1, 1999 (*Abstract only*)
	C22	Taguchi *et al.*, "Autoimmune oophoritis in thymectomized mice: detection of circulating antibodies against oocytes," *Clin. Exp. Immunol.* 40(3):540-553, June 1980 (*Abstract only*)
	C23	Taguchi and Nishizuka, "Autoimmune oophoritis in thymectomized mice: T cell requirement in adoptive cell transfer," *Clin. Exp. Immunol.* 42:324-331, 1980
	C24	Tong and Nelson, "A Mouse Gene Encoding an Oocyte Antigen Associated with Autoimmune Premature Ovarian Failure," *Endocrin.* 140(8):3720-3726, 1999

EXAMINER SIGNATURE:	DATE CONSIDERED: 12/30/05

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.

JAN 16 2005 PATENT & TRADEMARK OFFICE

Attorney Docket Number	4239-64790
Application Number	10/677,943
Filing Date	October 1, 2003
First Named Inventor	Nelson
Art Unit	1632
Examiner Name	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

	C25	Tong *et al.*, "*Mater* encodes a maternal protein in mice with a leucine-rich repeat domain homologous to porcine ribonuclease inhibitor," *Mammal. Gen.* 11:281-287, 2000
	C26	Tung and Teuscher, "Mechanisms of autoimmune disease in the testis and ovary," *Hum. Reprod. Update* 1(1):35-50, January 1995 (*Abstract only*)
	C27	Tung *et al.*, "Murine autoimmune oophoritis, epididymoorchitis, and gastritis induced by day 3 thymectomy. Autoantibodies," *Am. J. Pathol.* 126(2):303-314, February 1987 (*Abstract only*)
	C28	Van Voorhis and Stovall, "Autoantibodies and infertility: a review of the literature," *J. Reprod. Immunol.* 33:239-256, 1997
	C29	Vegetti *et al.*, "Premature ovarian failure," *Mol. Cell Endorinol.* 161(1-2):53-57, March 30, 2000 (*Abstract only*)
	C30	Wheatcroft *et al.*, "Detection of antibodies to ovarian antigens in women with premature ovarian failure," *Clin. Exp. Immunol.* 96(1):122-128, April 1994 (*Abstract only*)
	C31	Xun *et al.*, "Interspecies-specific ovarian autoantigens involved in neonatal thymectomy-induced murine autoimmune oophoritis," *Am. J. Reprod. Immunol.* 29(4):211-218, May 1993 (*Abstract only*)
	C32	Yan *et al.*, "Identification of Premature Ovarian Failure Patients with Underlying Autoimmunity," *J. Womens Health Gend. Based Med.* 9(3):275-287, April 2000
	C33	GenBank Accession No. AAF64393, "maternal-antigen-that-embryos-require protein; MATER; ooplasm-specific protein; OP1 [Mus musculus]." April 19, 2000 (2 pages)
	C34	GenBank Accession No. AC011470, "Homo sapiens chromosome 19 clone CTC-490M10, complete sequence." October 18, 1999 (40 pages)
	C35	GenBank Accession No. AC012107, "Homo sapiens clone RP11-45K21, WORKING DRAFT SEQUENCE, 25 unordered pieces." October 21, 1999 (45 pages)
	C36	GenBank Accession No. AC023887, "Homo sapiens chromosome 15 clone RP11-541M19, WORKING DRAFT CLONE, 9 unordered pieces." April 21, 2000 (48 pages)
	C37	GenBank Accession No. AC024580, "Homo sapiens chromosome 19 clone CTD-2621I17, WORKING DRAFT SEQUENCE, 69 unordered pieces." May 4, 2000 (32 pages)
	C38	GenBank Accession No. AF074018_1, "MATER protein [Mus musculus]." May 10, 2000 (2 pages)

EXAMINER SIGNATURE:	DATE CONSIDERED: 12/30/05

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.

JAN 16 2005

INFORMATION DISCLOSURE STATEMENT BY APPLICANT			
		Attorney Docket Number	4239-64790
		Applicati n Number	10/677,943
		Filing Date	October 1, 2003
		First Named Inventor	Nelson
		Art Unit	1632
		Examiner Name	

	C39	GenBank Accession No. AF143559, "Mus musculus maternal-antigen-that-embryos-require protein (Mater) gene, exon 1," April 19, 2000 (12 pages)
	C40	GenBank Accession No. AV367637, "Mus musculus 16 days embryo lung cDNA, RIKEN full-length enriched library, clone:8430436F06, 3' end partial sequence." November 5, 1999 (2 pages)
	C41	GenBank Accession No. NM_011860, "Mus musculus ooplasm (Op1), mRNA." February 28, 2000 (3 pages)
	C42	GenBank Accession No. NP_035990, "ooplasm [Mus musculus]." February 26, 2000 (2 pages)
	C43	GenBank Accession No. Z86039, "B. taurus mRNA for hypothetical protein (oocyte transcript)," September 11, 1997 (1 page)
	C44	[redacted]ugsp.info.nih.gov/BioResearch/lastbest.htm, "Two Things Every Little Girl Wants," downloaded July 27, 2000 (2 pages)
	C45	[redacted]www.nih.gov/new/NIH-Record/09_24_96/story07.htm, "Hope for Women Facing Infertility Treatment," downloaded July 27, 2000 (1 page)
	C46	[redacted]www.nih.gov/news/pr/jan98/nichd-30.htm, "Ovarian Disorder Places Women at Risk for Bone Loss, downloaded July 27, 2000 (2 pages)

EXAMINER SIGNATURE:	DATE CONSIDERED: 12/30/05

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.

OIPE JUN 27 2005 PATENT & TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Attorney Docket Number	4239-64790-01
Application Number	10/677,943
Filing Date	October 1, 2003
First Named Inventor	Nelson
Art Unit	1653
Examiner Name	Karen C. Carlson

U.S. PATENT DOCUMENTS

Copies of U.S. Patent documents do not need to be provided, unless requested by the Patent and Trademark Office. For patents, provide the patent number and the issue date. For published U.S. applications, provide the publication number and the publication date. For unpublished pending patent applications, provide the application number and the filing date.

Examiner's Initials*	Cite No. (optional)	Number	Publication Date	Name of Applicant or Patentee

FOREIGN PATENT DOCUMENTS

Examiner's Initials*	Cite No. (optional)	Country	Number	Publication Date	Name of Applicant or Patentee
MK	B1	WIPO	WO 02/32955 A1	25 April 2002	The Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services, The National Institutes of Health
MK	B2	WIPO	WO 02/48362 A2	20 June 2002	Incyte Genomics, Inc.

Examiner's Initials*	Cite No. (optional)	OTHER DOCUMENTS

EXAMINER SIGNATURE: MK	DATE CONSIDERED: 12/30/05

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.